文献类型：期刊文献

英文题名：Research Progress and Optimization Strategies of Bispecific Antibody Therapies for CLDN18.2-Positive Gastric Cancer

作者：Ji, Panpan[1];Li, Miaomiao[1];Chen, Jinyue[1];Wen, Tingting[1];Chen, Wanhong[1];Wang, Jing[1];Li, Juan[1,2]

第一作者：Ji, Panpan

通信作者：Li, J[1];Li, J[2]

机构：[1]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730020, Peoples R China;[2]Gansu Prov Hosp, Dept Gastroenterol, Lanzhou 730099, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730020, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Dept Gastroenterol, Lanzhou 730099, Peoples R China.|[10735]甘肃中医药大学;

年份：2026

卷号：57

期号：1

外文期刊名：JOURNAL OF GASTROINTESTINAL CANCER

收录：Scopus(收录号：2-s2.0-105049049288);WOS:【ESCI(收录号:WOS:001865976900001)】；

基金：This work was supported by the Natural Science Foundation of Gansu Province (Grant No. 23JRRA1288) and the Gansu Provincial Drug Research Project (Grant No. 2025GSMPA063). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

语种：英文

外文关键词：CLDN18.2; Gastric cancer; Bispecific antibody; Targeted therapy

摘要：CLDN18.2 is specifically overexpressed in gastric cancer tissues and represents an important emerging therapeutic target in gastriccancer treatment. Bispecific antibodies (BsAbs), a class of antibody-based therapeutics capable of simultaneously targeting two antigensites, have recently entered clinical development for the treatment of CLDN18.2-positive gastric cancer. This review systematicallysummarizes the molecular designs, functional subtypes, and clinical development of CLDN18.2-related BsAbs, while analyzing currentchallenges and potential optimization strategies. Currently, CLDN18.2-related BsAbs that have entered clinical development mainlycomprise three categories: T-cell engagers, T-cell costimulators, and immune checkpoint-blocking BsAbs. These agents havedemonstrated preliminary antitumor activity in later-line monotherapy and first-line combination therapy settings, with generallymanageable safety profiles. Optimization of target combinations, precise patient selection, strategies to overcome efficacy limitations, and improved safety management represent important directions for enhancing the therapeutic value of BsAb-based approaches.